RecruitingNCT06253169
HPV DNA Self-sampling in a General Practitioner's Office.
Benefit of Self-sampling for HPV DNA in a General Practitioner's Office to Improve Participation in Cervical Screening - The ASTRA Study.
Sponsor
Patient Organization Veronica
Enrollment
2,000 participants
Start Date
Mar 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
One of the limitations of organized cervical screening in the Czech Republic is the lack of participation in preventive gynecological examinations. The aim of the project is to evaluate the benefits of self-sampling for HPV DNA in general practitioners' outpatient clinics to improve population participation in cervical screening.
Eligibility
Sex: FEMALEMin Age: 30 Years
Inclusion Criteria3
- Signed informed consent for statistical data processing and consent to the processing of personal data
- Age 30+
- HPV test never performed or performed more than 3 years ago or patient does not know
Exclusion Criteria6
- Refusal to participate
- Pregnancy and puerperium
- Menses
- History of hysterectomy
- HPV test performed \<3 years ago with negative result
- Regular participation in screening and concurrent age 35, 45 or 55 years (test will be performed in the same year of screening).
Interventions
DIAGNOSTIC_TESTHPV DNA self-test
HPV DNA swab from the cervix performed by the patient herself.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06253169
Related Trials
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
NCT049774538 locations
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180239 locations
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT0721670360 locations
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT0695266078 locations